CHENGDA PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.25 CNY | +0.63% |
|
+6.29% | -24.30% |
| Sales 2022 | 411M 56.79M 4.73B | Sales 2023 | 414M 57.18M 4.77B | Capitalization | 3.93B 543M 45.27B |
|---|---|---|---|---|---|
| Net income 2022 | 106M 14.63M 1.22B | Net income 2023 | 91M 12.56M 1.05B | EV / Sales 2022 | 8.58 x |
| Net cash position 2022 | 1.38B 191M 15.89B | Net cash position 2023 | 1.36B 188M 15.69B | EV / Sales 2023 | 6.2 x |
| P/E ratio 2022 |
45.2
x | P/E ratio 2023 |
43.2
x | Employees | 504 |
| Yield 2022 |
0.59% | Yield 2023 |
-
| Free-Float | 33.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.63% | ||
| 1 week | +6.29% | ||
| Current month | -5.31% | ||
| 1 month | -6.10% | ||
| 3 months | -11.66% | ||
| 6 months | -29.69% | ||
| Current year | -24.30% |
1 week
17.78
19.41
1 month
17.4121.58
Current year
14.6025.91
1 year
14.6031.50
3 years
14.60117.50
5 years
14.60117.50
10 years
14.60117.50
| Managers | Title | Age | Since |
|---|---|---|---|
Gang Lu
CEO | Chief Executive Officer | 49 | 01/99/01 |
Chao Fei
DFI | Director of Finance/CFO | 45 | 01/05/01 |
Jian Li Ge
CHM | Chairman | 71 | 25/99/25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Yu
BRD | Director/Board Member | 58 | 01/19/01 |
Ping Wang
BRD | Director/Board Member | 75 | 26/19/26 |
Sun Liang Cui
BRD | Director/Board Member | 42 | 01/19/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 19.25 | +0.63% | 1,260,758 |
| 25/24/25 | 19.13 | +1.43% | 1,329,940 |
| 24/24/24 | 18.86 | +1.40% | 1,235,629 |
| 23/24/23 | 18.6 | +2.14% | 1,316,005 |
| 22/24/22 | 18.21 | +0.55% | 1,250,498 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Chengda Pharmaceuticals Co Ltd is a China-based company mainly engaged in customized R&D and production of pharmaceutical intermediates. The Company is also engaged in the production and sales of L-carnitine series products and active pharmaceutical ingredients (APIs). The pharmaceutical intermediate products include NP0805/NP0908, NP1205, NP0806, NP1011/1214, NP1709 and others. The L-carnitine series products are used in the fields of food additives, feed additives and raw materials. The APIs products include Buwaxitan, Vidagliptin, Elagoli and others. The Company's products are exported to the United States, Europe, Japan, Canada, the United Kingdom, Italy and other countries and regions.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -24.30% | 411M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 301201 Stock
